Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new ...

The FOXA1 protein is a potentially highly sensitive diagnostic marker for small cell carcinoma of the prostate and possibly ...

Most prostate cancers rely on male sex hormones, known as androgens, to grow. As a result, standard treatment focuses on lowering androgen levels or blocking their activity, but many tumors eventually ...

Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...

The FOXA1 protein is a potentially highly sensitive diagnostic marker for small cell carcinoma of the prostate and possibly other aggressive prostate cancer subtypes that are difficult to diagnose due ...

Researchers at Keele University have published the first investigation into the variation in the chemical makeup of calcifications caused by prostate cancer, in the hope of identifying new markers to ...

Screening for prostate cancer using a blood test likely reduces the risk of dying from prostate cancer and may also reduce the risk of dying from any cause. Screening likely makes little to no ...

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Targeted cancer therapies are an expanding field of effective therapeutic approaches. While previous chemotherapy agents indiscriminately killed rapidly proliferating cells, newer “precision medicine” ...